A recent trial of IL-1β blockade in people with type 2 diabetes showed improvements in glycemic control and pancreatic β-cell function [6], and additional studies to better define the potential role of IL-1β blockade in the treatment of diabetes are ongoing. Here, IL1B is linked to type 2 diabetes mellitus.